Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union

Our partnered journal Future Oncology recently published a Short Communication article describing trastuzumab-anns use from clinical oncology practices in seven European countries. Trastuzumab-anns is a biosimilar to trastuzumab, which is approved by the EMA and US FDA for treatment of HER2+ early and metastatic breast cancer as well as metastatic gastric cancer. View the full paper here.